NOXOPHARM LIMITED

==> picture [180 x 77] intentionally omitted <==

Date: 27 November, 2017 Sydney, Australia

ASX Limited

20 Bridge Street NOX AGM CORPORATE PRESENTATION SYDNEY NSW 2000

ASX: NOX

Sydney, 27[th] November 2017 : Noxopharm Limited (ASX:NOX) is pleased to provide to the market and shareholders the Corporate Presentation for today’s 2017 Annual General Meeting.

ABN 50 608 966 123

Registered Office:

Suite 1 Level 6 50 Queen St Melbourne VIC 3000 Australia

Operational Office:

Suite 3, Level 4 828 Pacific Highway Gordon NSW 2072 Australia

Board of Directors Mr Peter Marks

Chairman Non-Executive Director

To be held at 2.00 pm at the Sydney Sofitel Wentworth Hotel, Adelaide Room, Level 4, 61-101 Phillip Street, Sydney.

---------------------------------------------------

About Noxopharm

Noxopharm is an Australian drug development company with offices in Sydney and Hong Kong. The Company has a primary focus on the development of drugs to address the problem of drug-resistance in cancer cells, the major hurdle facing improved survival prospects for cancer patients. NOX66 is the first pipeline product, with later generation drug candidates under development. The Company also has initiated a pipeline of non-oncology drugs.

Investor & Corporate Enquiries: Company Secretary : Prue Kelly David Franks M: 0459 022 445 T: +61 2 9299 9690 E: [email protected] E: [email protected] www.noxopharm.com

Forward Looking Statements

Dr Graham Kelly Chief Executive Officer Managing Director

Dr Ian Dixon Non-Executive Director

This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “plan”, “should”, “target”, “will” or “would” or the negative of such terms or other similar expressions. Forward-looking statements are based on estimates, projections and assumptions made by Noxopharm about circumstances and events that have not yet taken place. Although Noxopharm believes the forward-looking statements to be reasonable, they are not certain. Forward-looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company’s control that could cause the actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statement. No representation, warranty or assurance (express or implied) is given or made by Noxopharm that the forward-looking statements contained in this announcement are accurate and undue reliance should not be placed upon such statements.

==> picture [694 x 345] intentionally omitted <==

Noxopharm

CEO REVIEW 2017 AGM

Noxopharm

Our objectives

For the doctor: 🔵 Drugs that boost the effectiveness of radiotherapy (and chemotherapy) ONCOLOGY …. with lower (better tolerated) treatment dosages For the patient: 🔵 Better survival outcomes without fewer side-effects

For the investor: 🔵 A technology platform with the potential to become standard of care …. with an aim of generating revenue in 2022 2

Radiotherapy … the best anti-cancer treatment we have

Noxopharm

==> picture [456 x 219] intentionally omitted <==

Limitation of radiotherapy 1. Dose-limiting toxicity

==> picture [72 x 73] intentionally omitted <==

Noxopharm

Limitation of radiotherapy 2. Metastatic cancer too extensive for radiation

==> picture [72 x 72] intentionally omitted <==

==> picture [263 x 325] intentionally omitted <==

==> picture [225 x 167] intentionally omitted <==

==> picture [280 x 210] intentionally omitted <==

Noxopharm

DARRT

Direct and Abscopal Response to Radio-Therapy

DIRECT Sensitisation of Radio-Therapy

Noxopharm 7

==> picture [190 x 127] intentionally omitted <==

==> picture [23 x 23] intentionally omitted <==

==> picture [23 x 22] intentionally omitted <==

DNA damaged. Cell attempts to repair the damage.

Extensive damage .. beyond repair……cell dies. Modest damage … repairable …. cell lives.

Most dosages of radiotherapy not high enough to deliver extensive damage to all cancer cells .… tumour survives.

NOX66

v Blocks ability of cancer cell to repair damage …. even modest damage becomes un-repairable …. cell dies v Does NOT increase extent of damage v No effect on healthy cells

DIRECT Response to Radio-Therapy

Noxopharm

==> picture [538 x 334] intentionally omitted <==

----- Start of picture text -----

Shrinkage of irradiated
Radiotherapy applied to large
Direct radio-sensitising effect
tumours
tumours for pain relief 8
----- End of picture text -----

DIRECT Response to Radio-Therapy

Noxopharm

==> picture [13 x 16] intentionally omitted <==

----- Start of picture text -----

9
----- End of picture text -----

==> picture [823 x 334] intentionally omitted <==

----- Start of picture text -----

NOX66
Shrinkage of irradiated Complete remission of
Radiotherapy applied to large
Direct radio-sensitising effect Direct radio-sensitising effect
tumours irradiated tumours
tumours for pain relief 9
----- End of picture text -----

ABSCOPAL Response to Radio-Therapy

Noxopharm 10

Exposed tumours respond

Non-exposed tumours respond

==> picture [824 x 350] intentionally omitted <==

----- Start of picture text -----

Low-dose radiotherapy Direct radio-sensitising effectRemission of irradiated tumours Abscopal response
10
----- End of picture text -----

Noxopharm

Features of an abscopal response

Rare – very rare phenomenon Complete – primary AND secondary tumours disappear Durable – potentially permanent Unrestricted – range of cancers reportedly involved Short treatment – single course of treatment (7-14 days) Low toxicity – low-grade radiation sickness

How might an abscopal response/bystander effect work?

==> picture [239 x 241] intentionally omitted <==

==> picture [239 x 240] intentionally omitted <==

Noxopharm

==> picture [239 x 241] intentionally omitted <==

==> picture [11 x 8] intentionally omitted <==

----- Start of picture text -----

12
----- End of picture text -----

DARRT

Noxopharm

Direct Effect Abscopal Effect

==> picture [175 x 121] intentionally omitted <==

External Beam RT

Ø Patients with multiple (>3) tumours Ø Irradiate 1-2 tumours (5 days) Ø NOX66 14 days

==> picture [120 x 156] intentionally omitted <==

Ø Scan + 2 months and 4 months

DARRT

Noxopharm

Direct Effect Abscopal Effect

==> picture [175 x 121] intentionally omitted <==

External Beam RT

Ø Prostate cancer (metastatic castrate-resistant) Ø Solid common cancers (eg. lung, breast, melanoma) Ø Rare cancers (eg. sarcomas)

DARRT

Noxopharm

Direct Effect Abscopal Effect

==> picture [125 x 94] intentionally omitted <==

==> picture [38 x 31] intentionally omitted <==

Brachytherapy

Ø[177] Lutetium-PSMA-617

Ø 4 x monthly intravenous injections of LuPSMA/10 days NOX66

Ø Prostate cancer (metastatic castrate-resistant)

Ø ? Kidney cancer

DARRT

Noxopharm

Where NOX66 + Radiotherapy needs a boost ……… NOX66-001 Phase 1b Study Georgia

Low-dose carboplatin (AUC4 – monthly)

400 mg NOX66 800 mg NOX66

5 patients: 1 progressive; 4 non-progressive

6 patients: 5 non-progressive; 1 partial response

Noxopharm

NOX66

+ external beam radiotherapy + brachytherapy + chemotherapy (carboplatin)

Idronoxil

+ intravenous dosage form + pessary dosage form

==> picture [419 x 326] intentionally omitted <==

Noxopharm

Ian Minns

Director, Clinical Development and Medical Affairs

NOX66 Clinical Development

Noxopharm 19

Review of 2017 – Where are we now?
Looking forward to 2018 – Where are we heading?
Moving NOX66 towards first registration - Radiotherapy
Chemotherapy and other research with NOX66
Sharing our progress
Communicating data in 2018 and beyond

Noxopharm

Review of 2017 – Where are we now?

Mid Year update Studies planned:
Chemotherapy (Carboplatin): Study Commenced (Georgia)
Radiotherapy: External Beam RT in prostate cancer (Australia)
Radiotherapy: Stereotactic RT in prostate cancer (Investigator) 4. Radiotherapy: Brachytherapy in prostate cancer (Investigator) 5. Radiotherapy: External Beam RT in solid cancers (Hong Kong) 6. Rare Cancers: collect evidence in rare cancer population 7. Chemo-radiotherapy: in solid cancers (ANZ, Georgia)

Review of 2017 – Where are we now?

Noxopharm 21

Mid Year update à 6 months later

Studies planned:

Chemotherapy (Carboplatin): Study Commenced

Recruitment completed, interim data presented

Radiotherapy: External Beam RT in prostate cancer
Radiotherapy: Stereotactic RT in prostate cancer
Radiotherapy: Brachytherapy in prostate cancer

Open for Recruitment Open for Recruitment Open for Recruitment

5. Radiotherapy: External Beam RT in solid cancers

6. Rare Cancers: collect evidence in rare cancers

Chemo-radiotherapy: in solid cancers

Studies combined: multinational study in radiotherapy (all tumours) - Ethics submission (Aust) planned December De-prioritised, following discussions with oncologists

Noxopharm

Review of 2017 – Where are we now?

Mid Year update à 6 months later à Moving to first registration Studies planned:

Chemotherapy (Carboplatin): Study Commenced
Radiotherapy: External Beam RT in prostate cancer

Open for Recruitment

Radiotherapy: Stereotactic RT in prostate cancer
Radiotherapy: Brachytherapy in prostate cancer
Radiotherapy: External Beam RT in solid cancers
Rare Cancers: collect evidence in rare cancers

Open for Recruitment

Studies combined: Multinational study in Radiotherapy (all tumours) - Ethics submission (Aus) in December

Chemo-radiotherapy: in solid cancers

Moving towards first registration study

Target Indication: NOX66 in combination with Radiotherapy for the treatment of patients with metastatic cancer

Studies:

NOX66-002A: Determine Dose of NOX66 (Prostate Cancer)

NOX66-006: Open Label, all tumours. safety and efficacy

NOX66-007: Randomised, common tumours. Efficacy in comparison to standard care

LuPIN Study:[177] Lu-PSMA and NOX66 (Prostate Cancer)

Expansion of[177] Lu-PSMA research

Other Radiotherapy Research (supportive data, for expanded indication in future) – e.g. brain, paediatrics, stereotactic, brachytherapy etc.

Noxopharm 23

Notes:

Different Global Regulators may modify indication for specific tumour types
• Indication may also list when treatment can be used
Indication will discuss how to use Radiotherapy with NOX66
Rare cancers may not be included in indication, however evidence is important
• Reimbursement is as important as Registration

Noxopharm

Moving towards first registration

Target Indication: NOX66 in combination with Radiotherapy for the treatment of patients with metastatic cancer

Studies:

NOX66-002A: Determine Dose of NOX66 (Prostate Cancer)

NOX66-006: Open Label, all tumours. Safety and efficacy

NOX66-007: Randomised, 2-3 tumours. Efficacy in comparison to standard care

LuPIN Study:[177] Lu-PSMA and NOX66 (Prostate Cancer): Supporting registration

Expansion of[177] Lu-PSMA research

Other Radiotherapy Research (supportive data, for expanded indication in future) – e.g. brain, paediatrics, stereotactic, brachytherapy etc.

24

Notes:

Different Global Regulators may modify indication for specific tumour types
• Indication may also list when treatment can be used
Indication will discuss how to use Radiotherapy with NOX66
Rare cancers may not be included in indication, however evidence is important

Reimbursement is as important as Registration

2020/21

2017

2018

242019

Noxopharm

Beyond the trials to reach registration

Manufacturing and formulation: Optimise NOX66 formulation; GMP Manufacturing
Pre-clinical / non-clinical : in vitro and animal studies to meet regulatory and other requirements for registration and marketing
Medical Affairs: Liaison with oncologists, advisory boards, congress attendance and presentation

NEW!!

Marketing: Develop Noxopharm presence, brand-naming, commercialization (including pricing) strategy

NEW!!

Noxopharm

Chemotherapy with NOX66

Which Combination(s)?
Which tumour type(s)?
When in disease pathway?
For how long?

https://en.wikipedia.org/wiki/Chemotherapy_regimen

Noxopharm

Chemotherapy with NOX66

Radiotherapy prioritised for pathway to registration
Duration of therapy and of trials
Clarity of treatment (i.e. combination with RT) across all tumours
Chemotherapy remains important to development
NOX66-001 study to complete in Q2 2018
Next study, to be a randomised trial ± NOX66, planned for H2 2018
- Cancer type(s) and chemo to follow from advisory meetings with doctors
Further studies
- Other tumour types, chemotherapy regimen and dosing
- Led by medical need, in discussion with doctors
- NOX66 alone (monotherapy) to be investigated

Communicating Trials Progress 2018

Noxopharm

Progress – based on Data Safety Monitoring Committee Review
Independent body – researchers and statisticians
Regular meetings during trials – expect ~6 across trials in 2018
Review overall progress à decisions on continuation
Findings of DSMBs will be communicated

• Trial Data at conferences

Contingent on significant milestones in trials (end of study, all patients through a pre-defined time point) – expect ~4 in 2018
Requires considerable planning (e.g. ASCO – meeting June, submit presentation in February)
Requirement that data are embargoed until presented
Where significant outcomes, top line result may be released as per ASX requirements prior to conference

Noxopharm

What will ‘good response’ look like ???

Looking at a new breakthrough cancer treatment:
In Non-Small Cell Lung Cancer trial (582 patients evaluated)
Compared with a standard Chemotherapy
- Median (50% of patients) overall Survival - 12.2 months compared with 9.4 months
- Median Progression Free Survival (time before disease worsened) – 2.3 months v 4.2 months (not statistically significant)
- Overall Response Rate (patients who had at least partial response) – 19% v 12%
  - Four Complete Responses v One
  - Mean (average) duration of Response 17 months v 6 months
- Common Adverse Reactions (>20% of patients) - fatigue, musculoskeletal pain, cough, dyspnea, and decreased appetite

http://www.opdivohcp.com/metastatic-nsclc/efficacy/clinical-trial-results

==> picture [180 x 181] intentionally omitted <==

Noxopharm

🔵 NOX66 clinical studies in Asian-centric cancers

• Hepatocellular carcinoma (liver cancer)

Gastric carcinoma

🔵 Identify KOLs and form collaborations

🔵 Identify potential partners.

==> picture [151 x 149] intentionally omitted <==

NYX-205

NYX-104

Peripheral
neuropathy
• Ulcerative colitis
Sclerosing cholangitis
Stroke
Concussion
• Head trauma
• Hearing loss

NYX-330

Noxopharm

• High cholesterol

Noxopharm

Key Messages

==> picture [65 x 125] intentionally omitted <==

WE EXPECT TO KNOW BY END OF 2017 OF THE SUCCESS OF OUR MISSION

WE AIM TO BE IN A REGISTRATION STUDY BY END OF 2018

WE AIM TO HAVE MARKETING APPROVAL BY 2022

==> picture [37 x 37] intentionally omitted <==

A SUCCESSFUL OUTCOME IS A MAJOR SHARE OF THE $100 BILLION ONCOLOGY DRUG MARKET REALISTIC POTENTIAL TO BECOME STANDARD OF CARE DRUG IN MANY CANCERS

ü Lean operation ü Experienced team

ü A number of key inflection points anticipated within next 12 months

ü Several potential blockbuster drugs candidates

Disclaimer

This presentation has been prepared by Noxopharm Limited a company proposed to be listed as [ASX:NOX] (NOX or the Company). It should not be considered as an offer or invitation to subscribe for or purchase any shares in NOX or as an inducement to make an offer or invitation to subscribe for or purchase any shares in NOX. No agreement to subscribe for securities in the NOX will be entered into on the basis of this presentation or any information, opinions or conclusions expressed in the course of this presentation.
This presentation is not a prospectus, product disclosure document or other offering document under Australian law or under the law of any other jurisdiction. It has been prepared for information purposes only. This presentation contains general summary information and does not take into account the investment objectives, financial situation and particular needs of an individual investor. It is not a financial product advice and the Company is not licenced to, and does not provide, financial advice.
This presentation may contain forward-looking statements which are identified by words such as ‘may’, ‘could’, ‘believes’, ‘estimates’, ‘targets’, ‘expects’, or ‘intends’ and other similar words that involve risks and uncertainties. These statements are based on an assessment of past and present economic and operating conditions, and on a number of assumptions regarding future events and actions that, as at the date of this presentation, are expected to take place. Such forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions and other important factors many of which are beyond the control of the Company, its Directors and management.
Although the Company believes that the expectations reflected in the forward looking statements included in this presentation are reasonable, none of the Company, its Directors or officers can give, or gives, any assurance that the results, performance or achievements expressed or implied by the forward-looking statements contained in this document will actually occur or that the assumptions on which those statements are based are exhaustive or will prove to be correct beyond the date of its making. Readers are cautioned not to place undue reliance on these forward-looking statements. Except to the extent required by law, the Company has no intention to update or revise forward-looking statements, or to publish prospective financial information in the future, regardless of whether new information, future events or any other factors affect the information contained in this presentation.
Readers should make their own independent assessment of the information and take their own independent professional advice in relation to the information and any proposed action to be taken on the basis of the information. To the maximum extent permitted by law, the Company and its professional advisors and their related bodies corporate, affiliates and each of their respective directors, officers, management, employees, advisers and agents and any other person involved in the preparation of this presentation disclaim all liability and responsibility (including without limitation and liability arising from fault or negligence) for any direct or indirect loss or damage which may arise or be suffered through use of or reliance on anything contained in, or omitted from, this presentation. Neither the Company nor its advisors have any responsibility or obligation to update this presentation or inform the reader of any matter arising or coming to their notice after the date of this presentation document which may affect any matter referred to in the presentation.

==> picture [386 x 207] intentionally omitted <==

----- Start of picture text -----

Contact
----- End of picture text -----

==> picture [301 x 208] intentionally omitted <==

==> picture [360 x 199] intentionally omitted <==

==> picture [286 x 214] intentionally omitted <==

AI assistant

NOXOPHARM LIMITED — AGM Information 2017

65437_rns_2017-11-26_837b661c-6781-44f8-912e-043c136edfc1.pdf

Date: 27 November, 2017 Sydney, Australia

ASX: NOX